Pirenzepine (di HCl)

Drug #580

Pirenzepine (di HCl) is a selective M1 antimuscarinic agent, which has a preferential action on the gastric mucosa, causing reduced gastric acid secretion. Pirenzepine (di HCl) is used in the management of peptic ulcer disease.

← Previous drug Next drug →

Primary Characteristics

It is of Natural origin and belongs to Benzodiazepine.

It belongs to Cholinergic muscarinic antagonist pharmacological group on the basis of mechanism of action and also classified in Antipeptic Ulcerant pharmacological group. It is also classified under Gastrointestinal Anticholinergics/Antispasmodics .

Molecular Weight: 424.3 · pK_a: 2.1, 8.1 · Solubility in Water: 1 in 5 · Solubility in Alcohol: 1 in 105 · Non-proprietary name: Pirenzepine (di HCl).

Molecular structure of Pirenzepine (di HCl)

Pharmacokinetics

Absorption: Pirenzepine (di HCl) has an oral bioavailability is 25% (±5%), pre-systemic (first-pass) metabolism accounts for 0.5% (±0.5%).

Distribution: Pirenzepine (di HCl) has a volume of distribution is 14 litre. plasma protein binding is 10 %.

Elimination: plasma half-life is 11 hr, renal excretion is 80 %.

Indications

Pirenzepine (di HCl) is primarily indicated in conditions like Benign gastric ulcer, Duodenal ulcer.

Contraindications

Pirenzepine (di HCl) is contraindicated in conditions like Renal failure.

Dosage

Pirenzepine (di HCl)'s dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
0.476 mg/kg	0.476 mg/kg	Every 8h	PO	-
Paediatric Dosage (20kg)
0 – 0	—	—		Not Recommended in this age group
Neonatal Dosage (3kg)
0 – 0	—	—		Not recommended in this age group

Drug Interactions

None recorded.

Side Effects

The signs and symptoms that are produced after acute overdosage of Pirenzepine (di HCl) are Anticholinergic effects.

Pirenzepine (di HCl) is known to cause more or less tolerable side effects which are usually transient. These include Disturbances of accomodation, Dry mouth.

Warnings / Precautions

Pirenzepine should be used with caution in patients with renal (kidney) impairment, particularly those with end-stage renal failure. Avoid use in patients with angle closure glaucoma.

Available Brands

None recorded.

Storage Conditions

Pirenzepine (di HCl) should be stored Tab.

Drug Classification

1.17.1.2 — Anti-peptic ulcerants